A clinical case of treatment HER-2 blockers cancer therapy-related cardiac dysfunction
Year: 2024
Type: article
Study design: Case Report
Abstract: This clinical case about of left ventricular systolic dysfunction with chronic heart failure associated with targeted therapy with trastuzumab and pertuzumab in a patient suffering from HER-2 positive breast cancer. The exogenous phosphocreatine (“Neoton”) was added to the standard treatment of chronic heart failure with sacubitril/valsartan, bisoprolol, spironolactone or empagliflozin. It made possible to achieve an additional increase in the left ventricular ejection fraction and preventing interruption of targeted therapy and continue it as before.
Authors: NMRC of Oncology named after N.N. Petrov of MoH of Russia, St. Petersburg, Russia, N.A. Kozyavin, E.A. Mureyko, NMRC of Oncology named after N.N. Petrov of MoH of Russia, St. Petersburg, Russia, M.I. Gluzman, V.S. Nikiforov
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4407564230